It is true that an ingredient found in Simparica TRIO, called sarolaner, has been associated with seizures, particularly in dogs with neurological disorders. Dog owner Lauren Wilson claims that ...

Sarolaner (contained in all Simparica products) is licensed by the FDA for the treatment and control of fleas and various ticks in dogs. Sarolaner with moxidectin and pyrantel (Simparica Trio ) is ...

Zoetis, Inc. today announced that it received FDA approval for Simparica (sarolaner) chewables, a once-monthly flea and tick medication for dogs.

On the back of box it says “Adverse reactions are tremors, ataxia, and seizures due to the ingredient Sarolaner. Use with caution in dogs with a history of seizures or neurologic disorders”.

Prevention of tick infestations (black-legged tick, Gulf Coast tick, and American dog tick) Selamectin/sarolaner topical can be used “extra-label” or “off-label” for chewing lice.

The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard ...

On the back of the box, it says adverse reactions may include tremors, ataxia and seizures due to the ingredient sarolaner. “Use with caution in dogs with a history of seizures or neurologic ...

Dose Confirmation of Sarolaner Administered Orally Against Induced Infestations of Dermacentor variabilis on Dogs (A166C-US-12-132, 2013; A166C-US-12-133, 2013). 9. Zoetis.

On the back of box it says “Adverse reactions are tremors, ataxia, and seizures due to the ingredient Sarolaner. Use with caution in dogs with a history of seizures or neurologic disorders”.

The study included dogs that were randomly allocated to one of four treatment groups: Credelio, Simparica TRIO, NexGard or untreated control. Elanco Animal Health Incorporated (NYSE: ELAN) is a ...

GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study ...